Biotech Industry · global
Germany’s Merck plans $1.3 billion acquisition of Silence, betting on siRNA drug to reduce phlebotomy
Divesiran controls red blood cell production by regulating iron metabolism, with a phase 2 trial showing signs of reduced phlebotomy needs. With a major pharmaceutical company now taking over, the next hurdle is to confirm the efficacy of quarterly dosing and long-term safety.
For patients with polycythemia vera, repeated phlebotomy is a treatment for controlling blood cell counts and an ongoing burden on daily life. An experimental drug that seeks to reduce the need for phlebotomy by targeting iron metabolism has now prompted a major acquisition: Germany’s Merck KGaA announced on October 19 that it had agreed to acquire the UK’s Silence Therapeutics in an all-cash transaction with an equity value of approximately $1.3 billion. The core asset is divesiran, a small interfering RNA (siRNA) drug preparing to enter phase 3 trials.
Under the terms of the transaction, Merck will pay $20 per American depositary share (ADS), a premium of approximately 130% to Silence’s closing price on the previous trading day. The company’s announcement listed an enterprise value of approximately $1.1 billion, a different valuation measure from the $1.3 billion equity value. The transaction is expected to close in the first quarter of 2027, remains subject to shareholder and regulatory approvals, and will proceed through a UK court-sanctioned scheme of arrangement. Merck plans to finance it with new debt.
Polycythemia vera is a chronic myeloproliferative neoplasm in which excessive red blood cell production raises hematocrit, increasing the risk of thrombosis. Divesiran is designed to reduce production of the TMPRSS6 protein in liver cells, thereby increasing hepcidin, which regulates iron metabolism, and limiting the iron available to bone marrow to suppress excessive red blood cell production. This strategy focuses on controlling disease manifestations and cannot yet be regarded as eliminating the abnormal cells that cause the disease.
The main clinical signal supporting the acquisition came from Silence’s phase 2 SANRECO trial, announced in August. The randomized, double-blind, placebo-controlled study enrolled 48 patients dependent on phlebotomy and evaluated subcutaneous divesiran injections every six or twelve weeks. The company reported a combined response rate of 88% across the two treatment groups, compared with 19% in the placebo group. Response was defined as requiring no phlebotomy during weeks 18–36 while maintaining hematocrit below 45%. During weeks 0–36, patients in the treatment groups underwent an average of 0.2 phlebotomies per person, compared with 2.1 in the placebo group.
However, the 88% figure was not the result for the quarterly dosing group alone. The response rate was 81.3% in the every-twelve-weeks group and 93.8% in the every-six-weeks group. The phase 3 trial, which Silence had originally planned to launch in the first half of 2027, will compare dosing every twelve weeks with placebo. This distinction directly affects the frequency of injections and clinic visits patients may face in the future. It also shows that subsequent trials must validate the specific regimen, rather than simply carry forward the strong impression created by the pooled data.
On safety, Silence said the phase 2 trial identified no new safety signals. Injection-site reactions were uncommon and self-resolving, and investigators reported two cases of grade 1 anemia. However, a 36-week controlled study involving 48 people remains insufficient to fully assess the risks of long-term regulation of iron metabolism. Improvements in hematocrit and phlebotomy frequency also cannot be directly equated with proven reductions in thrombosis, longer survival, or prevention of disease progression.
### Background
Major pharmaceutical companies’ investments in siRNA are expanding from technology collaborations to acquisitions of drug candidates with clinical data. The significance of this transaction lies in Merck’s willingness to commit funds to a rare disease therapy that has shown a phase 2 efficacy signal but has yet to complete pivotal validation. If the acquisition closes as scheduled, divesiran will gain access to greater development and commercial resources. Whether it can reduce patients’ phlebotomy burden over the long term remains a question for the phase 3 trial.